SCHEMBL3975993

SCHEMBL3975993

CCOC(=O)c1occc1-c1cccc(NC(=O)c2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.54
NPC1 O15118 7/20 0.54
SMN1; SMN2 Q16637 5/20 0.53
GAA P10253 1/20 0.53
ALDH1A1 P00352 3/20 0.51
MAPK1 P28482 2/20 0.51
MAPT P10636 2/20 0.51
LMNA P02545 1/20 0.51
POLB P06746 3/20 0.50
PKM P14618 1/20 0.50
MEN1 O00255 6/20 0.48
KMT2A Q03164 6/20 0.48
TSHR P16473 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
TP53 P04637 2/20 0.48
NR1H4 Q96RI1 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
KCNK3 O14649 1/20 0.47
KCNK9 Q9NPC2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3976513 0.86 KDM4E (0.47) RAB9ANPC1SMN1; SMN2GAAALDH1A1
SCHEMBL3978715 0.84 MGLL (0.61) RAB9ANPC1SMN1; SMN2ALDH1A1MAPK1
SCHEMBL27624297 0.84 KCNK3 (0.56) RAB9ANPC1SMN1; SMN2ALDH1A1MAPK1
SCHEMBL3982143 0.83 KCNK3 (0.52) RAB9ANPC1SMN1; SMN2ALDH1A1MAPK1
SCHEMBL3982536 0.81 TSHR (0.47) RAB9ANPC1SMN1; SMN2GAAALDH1A1
SCHEMBL6793571 0.78 RAB9A (0.76) RAB9ANPC1SMN1; SMN2GAAALDH1A1
SCHEMBL3977084 0.78 ALDH1A1 (0.52) RAB9ANPC1SMN1; SMN2GAAALDH1A1
SCHEMBL3977097 0.78 FNTA (0.46) RAB9ANPC1GAAALDH1A1MAPT
SCHEMBL3979355 0.77 MAPT (0.45) RAB9ANPC1SMN1; SMN2GAAALDH1A1
SCHEMBL3976847 0.77 SMN1; SMN2 (0.53) RAB9ANPC1SMN1; SMN2GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 RAB9A 2501/4885NPC1 1584/4885SMN1; SMN2 3697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.